

Your request

You requested the following:

I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.

1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as paediatric (age 17 and under).
2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight
 - NovoSeven RT
 - Nuwiq
 - Obizur
 - Refacto AF
 - Any other products
3. For patients treated with Advate in the last three months, please provide:
 - the number of haemophilia A patients treated prophylactically
 - the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)
4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight

- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Any other products

Our response

1. Our response to question 1 is provided in the table below:

Haemophilia A Patients	No. of Patients
Registered	13
17 Years Old and Under	0

2. 1 patient was treated with the product Refacto AF.
3. We have not treated any patients with Advate in the last three months.
4. We have not treated any patients with the products listed for severe Haemophilia A in the last 3 months.